that brings us to the stock of the hour is eli lilly.or more on this, we are joined by jared holz, managing director at mizuho securities. the result of this experimental drug by novo nordisk missed the target, but not by a lot. is is a proportional response by eli lilly to the novo nordisk news? jared: there is so much complexity to it. when you look at the data on a relative basis versus what the company message and what investors were thinking, it definitely came up short. in absolute terms, the data in terms of efficacy very solid. but when you look at what eli lilly currently has, it seems like lilly will still be the market leader as the combination is not good enough to really supersede it. scarlet: is there a lot of hammering for a new obesity drug that novo nordisk is working on? the current ones seem to be effective. jared: i agree with you. that has been a big part of my thesis around this space, the market demanding better efficacy results. 20% weight loss for most patients is really good. when you look at the data today, par

moments from now you will be hearing from the ceo of eli lilly. dave ricks will be speaking to david bernstein at the economic club of washington. let's give you a set up in terms of where we are standing with financial markets. unchanged for the s&p and the nasdaq after making a steady string of record highs post-thanksgiving. s&p and nasdaq 100 have stalled out before tomorrow's cpi print. yields getting across the curve before three-year bond auction in 30 minutes time. notable, dollar-loony is unchanged at the moment, although the dollar is the highest against the loonie since april 2020. trump's tariff that's are seen as hurting sentiment in canadian currency. the bank of canada is cutting rates by 50 basis points. we will keep an ion that as we get closer to the rate decision. since the election we have seen financial stocks outperform and in particular citigroup shares. the cfo today announcing that the firm is set to hit the high-end of its 2024 revenue guidance, and once there is more clarity on the outlook for capital, the bank does inte

back and losing weight, shares of novo nordisk getting skinnier after disappointing results and eli lilly zepbound getting approval to treat sleep apnea. >>> and american express and fedex and traders lay out their charts of the year as we head into the last few trading days of 2024. i'm melissa lee coming to live from the north dakota, on the tesk, tim, karen, steve, and mike khouw stocks rebounding sharply after early losses after austin gools bisaid he encouraged by the data today stocks did end off their highs of the session in all three majorin disys are down for the week let's turn to steve liesman. >> five days before christmas and the fed delivered to markets two dovish fed officials and a friendly pce austin telling cnbc in an interview that the funds rate is still substantially higher than the neutral rate so there is room for the fed to cut. >> that is why i say over the next 12 to 18 months, if conditions keep on the way that they have over the last 18 months, i think rates come down a fair bit more. >> he will vote on policy next year, the feds pce came out a tenth better tha

yeah. ..and eli lilly in the united states, the really big players in this game.? how much of a lead have they got? we think that they're, you know, miles ahead of the competition for a couple of reasons. the first of which is that, you know, obesity obviously is a huge space and we all know it now, but it was a little bit of a pharmaceutical graveyard in that, you know, either drugs just didn't work well enough or they had side effects such that they were too dangerous for people to use. so a lot of companies abandoned the field, whereas novo and lilly continued to pursue drugs for diabetes and obesity. and so they're really far ahead in terms of the innovation gap, just because this is their bread and butter, they've been working on it for a long time. and then secondly, for now, all of the drugs that work the best come in an injectable pen. so that is a pretty complex manufacturing process as opposed to making a pill. so both novo and lilly have invested billions and billions of dollars in building out their manufacturing network. so it's both of those factors

if you're going for alzheimer's drug go for eli lilly. think their alzheimer's drug is going to be a great standing over multiple years. as we head into 2025, i think it's time to look at the health care stocks which in my view have been quiet for too long. coming up, more on marvell technology after the early december earnings. doing so well. i'll tell you where i stand on opportunity in individual stocks following incredible conversations with members. coming up the lightning round. stay with cramer. the all new godaddy airo helps you get your business online in minutes with the power of ai... ...with a perfect name, a great logo, and a beautiful website. just start with a domain, a few clicks, and you're in business. make now the future at godaddy.com/airo your record label is taking off. but so is your sound engineer. you need to hire. i need indeed. indeed you do. our advanced matching helps find talented candidates, so you can connect with them fast. visit indeed.com/hire it all started with a small business idea. it's a pillow with

. -- rfk jr., they met with executives from eli lilly and pfizer.came out of that meeting? lauren: i'm to going with a good rapport. you have ceo of pfizer, ceo of eli lilly meeting with trump, and in comes the secretary, or the nomination, for the department of health and human services, rf fk jr., who is anti-vax and pro-making americans eat healthy again. those viewpoints make him public enemy number one for the business of pfizer and ely eli lilly, so i would say this reported meeting is a perfect example of trump bringing people together. it's reported it was a good conversation. as i said,s it lasted three hours, and he's working to bring the private and public sector together. and i also -- they also were working towards the moonshot of curing cancer. so a lot came out of that meeting, and apparently, at the end, he played his playlist off his ipad. [laughter] stuart: why am i not surprised? check futures, please, we're sill looking at some green. the opening bell is next. ♪ she does it like this when you do it like that. ♪ well, she does it

novo nordisk shares falling by the most on record after a failed attempt to leapfrog rival eli lilly the red-hot market for obesity drugs. novo's experimental obesity shot help the patient's lose an average of 20.4% of their weight over eight weeks, short of the 25% weight loss the danish drugmaker had repeatedly predicted. novo is a's biggest company and looks at two and the year deep and negative territory. let's bring in our correspondent for the latest. it was a remarkable day on friday when the top -- stock took a massive hit on the nose, when it's $25 billion wiped off -- $125 billion wiped off. >> no one is counting on this drug to position itself as a leader for weight loss drugs, and it released results of a late stage trial on friday, and investors were disappointed. the problem for novo was people did lose a decent amount of weight, 20% of your body weight does not sound bad, but the problem with novo is a promise too much. he promised before results of that it could deliver 25% weight loss, so it was confident and expectations were high, and that is what we saw such a str

eli lilly capturing the market in the billions and trillions if you go globally. consumers and another distribution opportunity for that . cheryl: eli lilly at 797, it's not a cheap stock. >> first trillion and the trillion dollar club that wouldn't be a tech. it would be healthcare. cheryl: home depot and a terror story asks you about that and lieu lieu lemon, netflix and nvidia. >> last two years going into the fed's easing and going into 2025 and as well as 57% of homes united states. if you're going to go you're going to go to home depot for the global leader in terms of getting your home right. ashley: yeah, the last earnings call they were not seeing that. next year is a new year. talk to me actifed ya though. >> running laps around the competition and no other game in town it's okay to sell into the strength and take house money off the table and rebalance and look for other opportunities in the market. cheryl: going and will computing for the chip. willow is the new chip and elon musk is impressed and the arm's race and in the first innings of that going f

we know of eli lilly. we know amgen could be a competitor.nd so this is, i guess, the crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 2030, 2035. we are perhaps serving one million or two million of those today. so, there is a huge market opportunity, and there is a place for more. and then, you're right, that in most markets when you get more competition, and also over time, pricing moves down, because you start treating those who accept, say, the higher price point -- in the u.s., that's commercial insurance -- and then, over time, you get broader access, and you get patients paying a lower price. so if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc. is some 40% lower than when we launched. that's often not mentioned in, say, the political deb

it was funded by eli lilly.re it, it shows people taking zepbound lost more weight. they lost 20.2% of their body weight. they lost 20.2% of their body wait. that's about 50 pounds. those treated with wegovy took off 13.7% or some 33 pounds. these drugs have different active ingredients. zepbound targets two, wegovy one. a study shows wegovy reduces heart attack and stroke. >> we keep learning more. thank you. >>> up next, the story behind this year's rockefeller center christmas tree and the family for whom it means so much. trade in any phone, in any condition and get samsung galaxy s24+ with circle to search, and watch and tab. all three on us. survive the holidays with samsung, powered by verizon. for more than a decade farxiga has been trusted again and again, and again. ♪ far-xi-ga ♪ ♪ far-xi-ga ♪ ♪ far-xi-ga ♪ ♪ far-xi-ga ♪ ask your doctor about farxiga. a chewy order is en route for monkey, who loves to climb. so mom uses chewy to save 40% on gifts that help keep the tree intact, and monkey good and grou

eli lilly up by more than 4%.is a heated competition between them over dominance in the weight loss drug category that has been a high flyer. just to give you a sense of how small the margins have to be for this to respond to this kind of way, the shot helped patients lose an average of 22.7% of their weight over 68 weeks, the novo nordisk drug, versus the expectation of 25%, and that was enough to sink them where they are not can, and it shocked the danish stock market the most. this goes back to the breadth, gainers or lifting everybody, and there's a lot of weakness. jonathan: just to be clear, that is the danish stock market. lisa: well, yes, and it is also telling that they danish stock market is composed of a stock that sells significant amounts to the u.s., not necessarily to the dates. jonathan: stoxx 600 europe having a difficult morning into the afternoon. coming up on the program, we catch up with jim caron of morgan stanley on the healthy selloff in equities. annmarie hordern joins us from washington,

eli lilly's weight loss drug zepbound helped people lose more weight than novo nordisk's wegovy.govy. >>> the price of bitcoin has hit $100,000. it has surged 45% since election day. >>> there is a famous pair of ruby slippers worn by judy garland in the wizard of oz up for auction. and bidding has already surpassed $1 million. the final live auction happens this saturday in texas. i'm sure it's going to be huge now with all the rave around wicked. >>> the mega millions jackpot has grown to $579 million. that is the tenth largest in its history after no one won the latest drawing, the cash option is worth $276.6 million. the next drawing is tomorrow night. what a great holiday season it would be if you won. season it would be if you won. ♪♪ mmmmmmm. repeat the sounding joy. [laughters] kinder joy. [laughters] open a world of surprise. my life is full of questions... mom, is yellow a light or a dark? how do i clean an aioli stain? thankfully, tide's the answer to almost all of them. why do we even buy napkins? —use tide. —can cold water clean white socks? it can with tide. do i ne

>> it is a terrible sector outside of eli lilly.ook at them, there are a lot of stocks that are very cheap and i think are overly hated. it's not a bad time to start looking around and thinking which ones might be worth buying. one of my favorites is gilead signs. it's done -- sciences. it's been hated since 2016, and there are a lot of stocks that fall into that same camp that i think are probably worth a look, things like pfizer or bristol meyers, what not. jack: al, there is a lot of skepticism about the so-called department of government efficiency which isn't actually a government. it's being run by two people, and in early pronounce appointments doesn't seem to understand what government spending does. >> i sense your skepticism. [laughter] so my surprise for '25 would be that doge is okay, that doge actually does something if useful. it's being run by elon musk and vivek ramaswamy. it has a fixed end date, july 4th, 2026. you know, ramaswamy noted, oh, we can save the -- floated, oh, we can save the u.s. government $2 trillio

alphabet and apple, we're not going to allow that and put in eli lilly.y inexpensive and i think we have to make the change we have time for one more. let's head to betsy in california >> caller: hey, jim. happy almost weekend >> right back at you. >> caller: my stocks are adobe, abercrombie and fitch, exxon and my christmas pick is home depot. >> these are nice. these are nice stores. your nice store, home depot which was up very big told we told people in the charity trust, buy that and it has been dead right amazon is my favorite retailer but it is also web services so i'm not going to say that. and the amazon advertising business is doing quite well and abercrombie. this is fashion and this is home this trades with the home companies. it does not trade with the fashion companies. of course, right and this is not taser, but axon is what i regard as police work papers it is the equivalent of like all sorts of stuff involving justice. let's put it that way. and then adobe which reports next week which is software that makes you create and i could argue -

last week, the fda approved eli lilly's zepbound were eli lilly's zepbound for treating sleep apnea in1 drugs is making inroads among adolescents with obesity as a solution to a growing problem. with cases tripling over the last 30 years, the american academy of pediatrics for some younger patients. cbs's janet shamlian explains why. >> reporter: 15-year-old jeremiah jimenez weighed 350 pounds by the time he was 13. but after less than a year on the weight-loss drug wegovy, he lost 65 and hopes to drop 80 more. what's that like? >> it feels good. i just feel stronger because i have incorporated strength training, as well. so i just feel empowered. >> these are once a week injections. >> reporter: suzie jimenez said she talked to her son's doctor about whether it would be suitable for him after she dropped 70 pounds on the same type of medication. >> he has turned into a different person. like, his light has just been lit. >> reporter: the number of prescriptions for young people for what is called glp-1 weight loss medications is skyrocketing. from more than 8,000 a month in 2020 to mo

. >>> and later, ro inking a deal with eli lilly. we'll talk to the ceo about the deal. i'm melissa lee, coming to you live from studio b at the nasdaq. on the desk tonight -- tim seymour, karen finerman, dan nathan, and guy adami. we start off with that big round number for the nasdaq. the index closing above 20,000 for the first time ever. today's nearly 2% move comes courtesy of some of the biggest names, pinging resh highs of their own. amazon, apple, meta, netflix, and tesla all hitting intraday records. and today's milestone comes about 4 1/2 years after the nasdaq first crossed 10,000. the biggest gainers in the nasdaq 100 over that period, nvidia, up 1300%. super micro just behind that. tesla, broadcom, palo alto each up 400%. so, does today's action give the all clear for that tech trade, guy? >> all clear, i love that all clear. for -- the six names we just had up on the screen, i was trying to figure out, where i have been on some of these things. apple, missed the boat, tesla, no question. netflix, facebook and google, we've done a decent job. so, all clear -

i want to talk to to you about eli lilly.dividend kind of guy, and lilly just hiked their dividend about 15%. heavy got a $15 billion buyback as well. are you buying? >> no, we're definitely not, and this is a case where the dividend hike works against the argument. they went from a .65% yield to a .74% yield. but the stock has gone from 100 to 800. it hasn't really moved all year. it's been kind of dead money through this huge 30% rally, but, stuart, why would a company that's making more money than they've ever made from a single drug be paying such a very low dividend? going back 10, 15, 20 years. eli lilly had a 3, 4 or 5% dividend yield the entire time, now it's way less than 1%. so we look to the dividend to see confidence from management that this free cash flow is going to expand. i think in this case they had a huge blockbuster, stock went up a lot, but management if isn't paying the share holders with cash from it. we're not attorney touching it. stuart: -- not touching it. stuart: going to. how about amgen? you've

eli lilly hospice weight loss drug winning over novo nordisk.ion of obesity drugs. let's get to 35 thousand feet and talk about the adoption of these. i'm sure in your world is busy. talk about the adoption and whether things have slowed or where you are still seeing the steep grove we saw over the previous year. evan: let's go back to three q results where we saw a bifurcation between eli lilly and novo. they were trying to draw demand in line with what you described. novo still had supply issues with assets like week ovi -- weg ovy. let's talk about the date it, largely expected but eli lilly has data that can go out to physicians to say ours is better. what is important is that novo has a data read out by the end of the year and could be better by zetbond. we found a trial posted on the website for clinical trials showing that novo has a co-formulation. a lot of moving parts, very exciting. fourth quarter is important because companies got beaten up in 3q. jonathan: what is better about it, delivery, performance, more effective? evan: weight

i tell you if i could take a match in light it to my head, i might say, eli lilly. but soon, the match goes out. roy in california. roy collects >> hey, jim, how's it going? >> couldn't be better. how about you, roy? >> can complain. i have a little concern, though. i'm looking at uber and with the expansion of limo, and i heard about a deal between waymo and waymo, i'm trying to figure out how to play it, dropped considerably the other day, with waymo. >> let me tell you what is going on with uber. we are now in a charters market. is there anything wrong with her? no. is there anything wrong with airbnb? no. bookings.com, they are all the same. when the chart is good, people buy them, and right now we are gripped in chart land and when charts are bad, people sell them, it shouldn't be that stupid, but it is. we are gripped by a wave of stupidity, the likes of which i haven't seen since maybe jefferson said the first amendment allows stupidity. incredible. it was in the federalist papers. i read it. i was going to be a history professor. anyway, i don't mind a day l

. >>> let's move onto eli lilly, announcing a $3 billion investment to expand glp-1 manufacturing capacity at its wisconsin facility today this after results were released comparing zepbound to wegovy patients losing 47% more weight on lilly's drug after 72 weeks joining us on the fast line for more is eli lilly's chief science officer. dan, good to talk to you again >> yeah, pleasure to be on, thank you. >> there's a lot of excitement surrounding this head-to-head trial, but there's one big question mark, and that is the tolerability profile will we get that data any time soon, and can we extrapolate at all from historical trials, where we saw the -- you know, the nausea and vomiting percentages, can we extrapolate that maybe lilly's profile looks better than novo's, seeing that at 72 weeks s versus 68 weeksh novo, that the side effects were lower? >> right, it's a good question we showed that patients on zepbound lost about 50 pounds, compared to the competitor, wegovy, patients lost 33 pounds. and we noted that the tolerability of the drug, the adverse effects, were similar to what we'v

results showed patients got weekly injections of eli lilly.they lost weight an average of 50 pounds after 72 weeks. that's compared to an average of 33 pounds for those who got the novo nordisk injection during that same time frame. calls for change in san jose what a new report is revealing about conditions at the san jose animal center, and the improvements that could be on the way. plus, we continue to follow that developing story in new york, where the ceo of united health was shot to death outside of a hotel. what witnesses say they saw and ho police kill the ceo of insurance company unitedhealthcare. police are describing the killing as a quote, brazen, targeted attack and not a random act of violence. brian thompson had just walked out of his hotel in manhattan this morning, when the gunman walked up and shot him and continued to fire as thompson fell to the ground. it was captured, we're told, on surveillance camera. the gunman was also seen riding away on a rideshare bike toward central park. >> it appears the suspect was lying in wai

you like eli lilly? >> yeah.se race for the drug loss and say you got lucky and picked the winning horse. no, it's based on science and a study came out head-to-head comparison between zepbound and wegovy that eli lilly zepbound leads to more weight klotz less side effects and that's not by accident. if we get into the science, it's because lily's drug targets two re-scepters and -- receptors and niveau dorman disk is one. >>-- novo nordisk. >> it's creating adverse effects with these drugs. stuart: other pick is inodata. >> talked about palantir and going for them and that's another ai play and under the radar ai play and in a data providing services to all the major ai players and they are the service provider and pick and shovel play growing at tremendous rate accelerating from 35% to 65% to now over 135% and stocks hitting new high. stuart: yes, it is. thank you, lieu. indata >> who is he going with him today? reporter: he's on capitol hill and really digging his heels in and media turning him in for brett ka

that's good for eli lilly.drugs help you lose more weight, the fda said there is no more shortage of the key ingredients, it is down 19%, 3% because they are testing obesity pill. 2,025 is the euro who could be the skinniest person alive. stuart: 19% down because of slight missing expectation for the weight loss drug. lauren: this company is negative for the year after all of this type, there are a lot of competitors coming in and losing one fifth of your body weight doesn't cut it. stuart: let's move on. occidental petroleum and sirius xm. lauren: berkshire hathaway uping a stake in both companies. they now own 28% of sirius xm. stuart: carnival is up. lauren: they are up 2%. carnival reported stronger demand, stronger revenue, they are predicting 20% earnings growth in 2,025. not only are we booking cruises and sea voyages but spending more on them. ahead, the deadline for the government shutdown is midnight tonight. the house failed to pass the trimmed down deal, that trimmed down deal had been backed by tru

dexcom also making gains eli lilly up 2% 6% dexcom up 6% >>> news on the ipo front. pippa has that for us. >> venture global, they are an exporter filed to go public. the proposed size and price have not yet been released. the company was looking to raise $3 billion through its ipo they are exporting at their pass they have been exporting since 2022 this comes as we expect to see ray demand in lng exports. venture dmroebl global has fileo public >>> rebounding retail. the best day in a month heading into a critical holiday shopping weekend. we will break it down, get the setup. the top picks for next year. we are live at the new york ew stock exchange you are "closing bell" on cnbc . >>> we are back. retail stocks getting a boost. joining me now is matthew boss with his top picks i want to start with the dud, nike we talked many times i know that there's a reboot here what do you attribute to the price action in that stock wasn't it up and down? >> 2q results were in line with expectation. that created a relief rally. as the call progresses, you heard that this is go

we have data from eli lilly's oral drug coming in 2025.e studies and that will be a big deal. we have talked about how people want an oral version of these drugs. the current medications are a weekly injection. for a lot of people that is not super appealing although for a lot of people it is because clearly there is no issue for demand. but in some other markets, pills are preferred. so we have a lot of companies that are trying to make oral versions of the drugs including lily and novo. we have structure, viking, smaller companies. pfizer as well. lily has phase 3 data from their drug coming out in 2025. we're going to see that. you're going to see other companies coming out with data from other trials. the competition is going to continue heating up. insurance coverage is also a place to watch. we had the biden administration proposed a new rule that would allow medicare, the government health insurance program for people over 65, to cover weight loss drugs. so it will be up to the trump administration in a few months whether to pass th

thank you for joining us >>> we have breaking new related to eli lilly and angelica has the details >y is announcing boostin production of glp-1s eli lilly saying the goal is t meet growing demand for th medicines for debeaties an obesity. the goal is to manufacture the injectible medicines and putting the medicine into the pens you need this is the latest from el lilly in the race to scale u supplies the company has committed $2 billion to manufacturing since 2020 those things don't happe overnight. lilly expects to start construction next year and t start making medicines in 2028 >> thanks. >>> up next star technician jeff degraph is flagging a part o the market that is showing animal spirit and it is no bitcoin. he explains after the break. but could be due to a buildup of amyloid plaques in the brain. the sooner you talk to your doctor, the more options you may have. learn more at amyloid.com. hi, i'm damian clark. i'm here to help you understand how to get the most from medicare. if you're eligible for medicare, it's a good idea to have original medicare. it gives you coverage fo

then went to a drug company, eli lilly, headed eli lilly u.s.a., then became secretary of hss.an unusual appointment. even if you look at it, all of us have management and experience. i ran a major research university, the university of wisconsin of madison, which hospitals and a huge healthcare system and a huge bio science enterprise. so all of us have had very different experience in rfk jr. if you listen closely to the republicans, they're saying nice things about their conversations, but let's see what they actually do when he gets cross examined and when the fbi's report comes in. so i'm not sure as other people are that he's going to be automatically confirmed. >> that's interesting. you know, i guess the question in light of all of it, madam secretary, is how we, as citizens. i mean, we get lost in process, and we talk about the political side. but at the end of all of this are the american people who suffer or benefit from these decisions and these decision makers. if you're advising the american people, what would you be advising them right now about their health? abo

and it's zepbound by eli lilly. i would love to hear from david ricks. >> and we will. nbc cfo council is underway. >> let's get right into it. the question is one way to think about policy is how you balance risk. and things have maybe changed a little bit since we last talked in november. tell me how you judge the balance of risks between inflation potentially coming back or stalling, and potential weakness in the job market? >> maybe i should start on the positive side, which is i think inflation's come down a bunch, and i'm encouraged with where it's headed. a lot of people on the labor side were worried there was a cliff there, and that also seems to not be the case. both sides of our mandate, we seem to be heading in the right direction. today is no promise of tomorrow, so you have to think hard about where you're going. i see positives on both sides, but i see risks on both sides. on the inflation side, we talk about the progress, but we're still in the mid 2s, not at 2, so we're still above our target. on the employment side, you can't ignore last month's jobs r

reportera: eli lilly dijo que su medicamento para perder peso superÓ su principal competidor, wegovy.wegovy la pelea de peso fue menor. el estudio fue realizado por la misma compaÑÍa que lo produce, pero mÉdicos no relacionados con la empresa destacan la efectividad. >> el hecho de que la misma compaÑÍa se estÁ echando porras, eso no ayuda mucho. pero eso concuerda con lo que vimos. reportera: el estudio reflejo que mÁs del 30% de usuarios de zepbound perdieron mÁs peso. los resultados del estudio estÁn sujetos a una revisiÓn por pares, y serÁn presentados en una conferencia mÉdica el prÓximo aÑo, pero expertos dicen que por estos hallazgos serÁn favorito entre los productos. ilia: elon musk y vivek ramaswamy proponen que en el paÍs no se vuelva a cambiar la hora en primavera y otoÑo. dicen que esta prÁctica es ineficiente y fÁcil de cambiar. ambos estarÁn a cargo del departamento de eficiencia gubernamental de donald trump. jorge: el papa francisco tiene un nuevo papa mÓvil, una versiÓn elÉctrica fabricada por mercedes benz. estÁ adaptado para velocidades bajas. ilia: la nasa restabl

that the sector doesn't need >> meantime, the fda affirming today that the active ingredient in eli lilly'srtage and it's telling them stop com founding found pounding, they they're them be a gz news for eli lilly, but the stocks are not up on this news. >> they lost all of the momentum they had earlier this year it's been a very tough stretch the last three months in particular i think the supply/demand metrics that we look at continue to favor the companies, just not enough clearly, a good headline for lilly today and novo's will come in time and we have hims and other companies can they compound, can they not does this -- is there any reversal here at any point i was surprised to see the stock down and again, pharmaceutical stocks in general had been super weak with the closure of the deal, downing of the deal, and yet the stock, we saw the reaction in today's session, so imagine if semaglutide comes off the shortage list. >> it's tough to know exactly when they'll get online in producing these drugs at scale, but it's just a matter of time >> all right we want to touch on vertex it has

. >>> coming up, the fda approaching eli lilly's weight loss drug to treat sleep apnea.that and some moves in the trump administration in the healthcare world with dr. scott gottlieb. you can get the best of squawk pod on your favorite podcast app and listen anytime. we're coming right back. >>> welcome back to "squawk box." president-elect donald trump's an transition team pushing for withdrawal on the world health organization. the u.s. the u.s. is the w.h.o. biggest funder. that process was never completed and president biden later restarted relationships and relations, i should say, with the agency. joining us to talk about that and so much more of the trump administration plans and news on weight loss drugs and all advertising thing which i don't know if you follow this, joe. rfk saying no television advertising for drugs. i agree. >> i agree. >> i agree, too. i'm interested you do agree because the big push on that was the first amendment argument for a long time. >> i know. i don't like them. i don't know if you just say you are not allowed to do them. >> the ques

semaglutide only does one thing. >> this study was funded by eli lilly. switch to zepbound or mounjaro? >> wegovy is incredibly effective. the question is what are the goals? having said that, if someone is not responding to wegovy or ozempic, yeah, i would think this opens up the conversation should we switch them to something like zepbound. >> what should people consider before starting these medications? >> you know, these are not easy to tolerate, especially upfront. two, we don't know how long you need to be on these medications. i caution everybody. there's a lot of interest in them. know that if you commit yourself to a few doses, you're committing yourself to unclear amounts, maybe years of therapy. we need to figure out who can be safely weaned off. >> dr. gupta, thanks so much. >>> the fbi is investigating mysterious flying objects over the skies of new jersey. some people say that unexplained drones have been hovering over their homes for weeks. nbc news correspondent stephanie gosk spoke to locals. >> it's not a plane. >> reporter: mysterious

so if you're taking eli lilly's zepbound. you'll lose 22%. novo's wegovy, 17%.s do 25 and it didn't happen, you've got a problem for shareholders was the market is extremely competitive. and this was not a pill. stuart: my favorite subject. down 20% almost. or all right, move on. trump, i believe he made some kind of move with his shares of djt. he's not selling them? if. lauren: no, he's not. he's moving them into a trust. he transfer thed his entire stake, which is worth over $4 billion or just over half of the company. djt down today, it's more than doubled this year because the president-elect will be president in a few days. stuart: address bitcoin, because that's having a rough day. >> lauren: it's at 95,000 now. it hit 108 just a couple days ago. cathie wood, her ark fin-tech fund offloaded almost $4 million of coinbase, the largest crypto exchange. stuart: and that's gone down too. the tesla rally. man, that's lost some steam, hasn't it? if look at it, another 3%? lauren: between bitcoin and tesla, this is the trump trade. and if djt at that too. so tesl

last week we had the ceo of ro and they had announced a deal, a partnership with eli lilly to sell theuld be cheaper. and some are saying that that partnership signals that it is not in shortage. why would they launch this new product line that so many people would want if this drug was in shortage. >> you know that the pens were in shortage to a great deal causing a lot of the problems. you think about $400 for a vial, that is competing directly with these compounds and i don't know why you would take a compound if you get that straight from lilly. >> for the same, yeah. >>> meantime, nike is on dig to report earnings on thursday. the sportswear giant could be due for the most positive results in nearly a year. >> the options market is implying a one day move of 7% less than the long term average move of 6% but over the last eight quarters it's moved around quite a lot, closer to 9%. we saw calls significantly outpacing puts and it was the december 80s those are the ones that expired this friday that were most active. we saw about 4,000 of those trading for $2.34 a contract that was e

stuart: you've got to show me eli lilly. i know there was a contest here on weight loss drugs.ren: i've got the numbers. eli lilly's own study shows users of its zepbound lost 20% of their body weight after taking the drug for 72 weeks compared to 14% for wegovy but this data could help give lillian edge when doctors are prescribing the drugs. stuart: wait a minute, 20% -- lauren: versus 14. stuart: after 72 weeks? lauren: yes. stuart: it's a long time to wait isn't it? lauren: you want the pill and instant gratification. who wants to wake up 20% lighter. stuart: next case is foot locker. lauren: down big time and cut their outlook for the year, more promotions, weaker spending, pushing the company to post a loss in the third quarter. the consumer is selective. we are spending a lot of money but we're picking where we're spending it and apparently not at foot locker. stuart: let's move on from this. i want to go back to the breaking news. we can now confirm through police sources that the ceo of united healthcare, brian thompson was shot and killed outside the hilton hotel in m

drug maker eli lilly says it should be used with both diet and exercise. the bay there from san ramon to danville and dublin. some wet weather through 580. also through milpitas south of hayward. 280 to 880, i should say getting some wet weather. and then right here, the santa cruz mountains. so periods of scattered showers today, the level one system, breezy south winds. and we're going to have some rough surf out there not only for today but for the weekend. temperatures right now are in the 50s with the cloud cover, but it is kind of messy out there with the temperatures a little bit above average. we're going to end up a cool winters day today with those breezy winds subsiding throughout the afternoon. we'll have more news coming up after the break. but do they really? do they see that crick in your neck? that ache in your heart? will they see that funny little thing that wasn't there last year? a new bounce in your step? the way your retinal scan connects to your blood sugar? at kaiser permanente all of us work together to care for all that is you. a

so eli lilly, at least in the first head to head a, the winner.uart okay, got that. apple, they just revealed whose a.i. chip they're using. this is important. whose chips are they using? >> amazon. can you believe that? so sort of competitors become partners in many cases. it's the aws which is amazon's cloud unit, their custom a.i. chip. they said they're evaluating if apple can also use it for if things like apple intelligence, but so far they've been a great partner in terms of using a work s for siri, music and other thing for the apple products. stuart: this is what ray wang was just talking about, the right? >> they did. so we're in the middle of this amazons investor conference which is where we're getting all of this the day -- data coming out. amazon has unveiled the train yum 22 chip and also 3 chips for a.i. we're herring more about them -- hearing more about them. stuart: amazon, all-time high, i think, at a 260? yes, all for heym high on -- all time high. when does meta think they will have nuclear power ready to go? i ask because i'

eli lilly's drug but company officials say this partnership will make it easy for patients to access all in one place. >> there is increased scrutiny of the health care system after last week's murder of unitedhealthcare ceo in new york. the attacker is believed to have acted out of anger against denials by health insurance companies and corporate greed. reports show as many as 30% or more of all health care claims are denied, depending on the insurance company. fewer than 1% of patients appeal them when it comes to taking on the insurance company. people are urged to start by checking their policy if their care should have been covered. they can appeal as many as three times. people are also urged to find the reason for the denial, which usually comes in a letter, or by calling the insurer. >> don't ever give up. fight for your rights. you know you you pay for your insurance and you have a right to be covered on your policy. >> if the denial says that the claim is not medically necessary. ask your care provider to write a letter outlining why you needed the treatment. be sure to kee

the pharma and biotech space has been a focus for investors with eli lilly having a big year and forsame for biogen. what other names should be on your radar? kevin is biotechnology analyst at bmo. good to see you. >> thanks for having me. >> let's begin with lilly. it's rallying again today. obviously, it's off its highs. the valuation is moderated. but what's the story and has it changed at all? >> the story a lot last week we had novo data disappointed most. that was novo's answer to zepbound. that's kind of not part of the picture now. my focus turns to 4 q where expectations are still pretty high. i think for the full-year consensus or guidance is really important. next year consensus is $28 billion for all of lilly's zepbound and mounjaro, about 26, that's going to set the tone. we're focused on that, and i think that will be -- >> the adverse surprise for novo, is there any read through at all, either pro or con for lilly or the area? i wonder how fast the challengers might ho>> lilly's the best products. toppling that will be challenging. novo had lofty expectations and faile

. >> segun eli lilly esto representa un 47% mas de perdida de peso con z-bound frente a weigobi precisamenten este estudio participaron 751 adultos de estados unidos y puerto rico y todos con sobrepeso y tambien obesidad. >> aunque zed down mostro ser mas efectivo en terminos de perdida de peso, wegovi tiene tiene beneficios adicionales para la salud del corazon. >> invernal tormenta invernal atraviesa los grandes lados de la tambien el noreste del pais. >> las nevadas son intensas, hay fuertes vientos y lluvia helada y esto va a continuar. >> el mal tiempo ya dejo imagenes como las que ven en su pantalla en ohio, por ejemplo, el peso de la nieve provoco el colapso de un techo en una e escuela y un lavadero de autos en en pensilvania, un bloque de hielo destruruyo el parabrisas un auto, ademas de multiples accidentes. >> pero, ¿por que se estan produciendo estas intensas nevadas? >> pues aqui esta nuestro jefe de meteorologia, carlos robles, para explicarlo. >> delante, adadelante, carlos. >> arantxa, para que tengas una idea visual de lo que representan cinco pies de nieve acumulada en los

. >> it's sold by eli lilly. >> and this is the first approval of a medicine for obstructive sleep apnea and it's specifically for people with obstructive sleep apnea and obesity. they suspect that it is the weight loss that's happening with this medicine that could be helping with the sleep apnea, obstructive sleep apnea affects an estimated 30 million americans, or perhaps even more. experts say a lot of folks don't even realize that they have it. it's characterized by this sort of closure of the upper airway when folks are sleeping, and that can lead to real sleep disruptions and significant health problems that are associated with it. >> it is closely linked with obesity, and even before this drug was approved, weight loss was recommended as a treatment to potentially reduce its severity. now, eli lilly ran two trials, two major trials in sleep apnea with this medicine. >> one with the medicine compared with placebo alone. >> so when patients weren't taking anything else and the other one on top of therapy with a cpap machine. so those big machines that folks have to wear when they h

. >> today, new preliminary data released by eli lilly, the maker of zeplin, suggests that while bothand zeplin showed a significant weight loss benefit after 72 weeks on treatment, people with obesity or who were overweight with another medical condition treated with deathbound lost more weight compared to people on wegovy. the study has not yet undergone further peer review. >> several of the medications are actually combination medications and that's because weight regulation is so complex that there are multiple different pathways involved. and sometimes targeting one is not as effective as targeting two pathways at the same time. and so we see that here with wegovy, which is associated with 14% total body weight loss versus tirzepatide or set bound, which is associated with 20% total body weight loss. >> in response to the study, novo nordisk, the maker of wegovy, saying in part wegovy is the only obesity medicine proven to reduce the risk of major cardiovascular events such as death, heart attack or stroke in adults with known heart disease and with either obesity or overweight.